Design, Synthesis, and Structure-Activity Relationship Study of μ-Conotoxin KIIIA toward Na_V1.4.

Area of Science:

• Biochemistry
• Pharmacology
• Molecular Biology

Background:

• Na_V1.4 sodium channels in skeletal muscle are key targets for neuromuscular disorder treatments.
• The conopeptide KIIIA is a small inhibitor of Na_V1.4, but its therapeutic use is limited by potency and complex synthesis.

Purpose of the Study:

• To design and synthesize novel analogues of KIIIA with improved potency and stability for Na_V1.4 inhibition.
• To evaluate the therapeutic potential of these optimized analogues for neuromuscular disorders.

Main Methods:

• Computational modeling was used to design analogues with added positive charges.
• Analogues were synthesized and their inhibitory potency (IC₅₀) against Na_V1.4 was determined.
• Enzymatic stability (t_1/2) and selectivity against other Na_V subtypes were assessed.
• In vivo muscle relaxation studies were performed.

Main Results:

• Optimized analogues [K7R, A15R]KIIIA-1 and [S5R]KA showed significantly increased potency against Na_V1.4 (IC₅₀ = 20.5 nM and 5.1 nM, respectively).
• The analogue C4Pen, incorporating penicillamine for stability, maintained high potency (IC₅₀ = 11.1 nM) and improved stability (t_1/2 > 8 h).
• Both C4Pen and [S5R]KA demonstrated preferential inhibition of Na_V1.4 over other subtypes and induced potent muscle relaxation in vivo.

Conclusions:

• Structure-based optimization, including electrostatic mutagenesis and penicillamine-mediated stabilization, successfully yielded potent and stable Na_V1.4 inhibitors.
• These optimized peptides represent promising therapeutic candidates for neuromuscular disorders.